Related Experiment Video
Updated: Jun 5, 2026
Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
[Anti-sclerostin antibodies]
1Third Department of Medicine, Teikyo University Chiba Medical Center.
Abstract:
Sclerostin is a secreted protein from osteocytes that inhibits Wnt signaling. Wnt signalling plays important roles in osteoblastic differentiation hence bone formation. Therefore, inhibition of sclerostin promotes bone formation. A monoclonal antibody has been generated against sclerostin, which has been shown to stimulate bone formation and increase bone volume in rodents and primates. Preliminary data on human showed this antibody increases markers for bone formation. Clinical phase 2 study using this antibody in postmenopausal osteoporosis was initiated in 2009, of which results are anticipated.
Insights
Inhibiting sclerostin, a protein that blocks bone formation, can promote bone growth. A new antibody targeting sclerostin shows promise for treating osteoporosis by stimulating bone formation.
Area of Science:
- Bone biology and endocrinology
- Osteocyte signaling pathways
- Pharmacological interventions for bone diseases
Background:
- Sclerostin, secreted by osteocytes, negatively regulates Wnt signaling.
- Wnt signaling is crucial for osteoblastic differentiation and bone formation.
- Targeting sclerostin offers a potential therapeutic strategy for bone loss.
Purpose of the Study:
- To evaluate the efficacy of a monoclonal antibody against sclerostin.
- To assess the antibody's effect on bone formation markers and bone volume.
- To investigate the potential of sclerostin inhibition in treating osteoporosis.
Main Methods:
- Development of a monoclonal antibody targeting sclerostin.
- Preclinical studies in rodents and primates to assess bone formation and volume.
- Preliminary human studies measuring bone formation markers.
- Initiation of a Phase 2 clinical trial for postmenopausal osteoporosis.
Main Results:
- Sclerostin antibody demonstrated stimulation of bone formation in preclinical models.
- Increased bone volume observed in animal studies.
- Preliminary human data indicated increased bone formation markers.
- A Phase 2 clinical study in postmenopausal osteoporosis is underway.
Conclusions:
- Sclerostin inhibition is a viable strategy for enhancing bone formation.
- The anti-sclerostin antibody shows therapeutic potential for osteoporosis.
- Further clinical evaluation is warranted to confirm efficacy and safety.
